コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 platelet-derived growth factor receptor and vascular endothelial growth factor receptor 2.
2 ability complex class II(low)) and expressed vascular endothelial growth factor receptor 2.
3 ctor (VEGF) and its major mitogenic receptor vascular endothelial growth factor receptor 2.
4 pha and a conventional IgG antibody to mouse vascular endothelial growth factor receptor 2.
5 es in vascular endothelial growth factor and vascular endothelial growth factor receptor 2.
6 nase inhibitor with activity against MET and vascular endothelial growth factor receptor 2.
7 immature (CD11c(+) MHCII(low)) and expressed vascular endothelial growth factor receptor 2.
8 s blocked by a neutralizing antibody against vascular endothelial growth factor receptor-2.
9 howed less internalization and activation of vascular endothelial growth factor receptor-2.
10 67, vascular endothelial growth factors A/C, vascular endothelial growth factor receptors 2/3, angiop
11 repressor engrailed repressed expression of Vascular Endothelial Growth Factor Receptor 2, a marker
12 on of NANOG which mediates the expression of vascular endothelial growth factor receptor-2, also know
13 osine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 and epider
14 showed that GA inhibited the activations of vascular endothelial growth factor receptor 2 and its do
15 nd the angiogenic receptor tyrosine kinases, vascular endothelial growth factor receptor 2 and platel
16 Shc activation requires the tyrosine kinases vascular endothelial growth factor receptor 2 and Src.
17 human immunoglobulin G1 antibody that binds vascular endothelial growth factor receptor-2 and blocks
18 hrough a nonclassical pathway dependent upon vascular endothelial growth factor receptor-2 and downst
19 Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epider
20 not PKD1, was required for the expression of vascular endothelial growth factor receptor-2 and fibrob
21 part through modulation of the expression of vascular endothelial growth factor receptor-2 and fibrob
22 naling, known to induce Notch, by repressing vascular endothelial growth factor receptor-2 and neurop
23 stimulated macrophages were able to activate vascular endothelial growth factor receptor-2 and the PI
25 uantification of subsets coexpressing CD133, vascular endothelial growth factor receptor 2, and chemo
26 4, alpha-smooth muscle actin, CD31, phospho-vascular endothelial growth factor receptor 2, and p42/4
27 of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearr
28 eas murine endothelial cells expressed CD31, vascular endothelial growth factor receptor 2, and von W
29 od mononuclear cells expressing CD34, CD133, vascular endothelial growth factor receptor-2, and chemo
31 thelial cell markers CD31, endoglin (CD105), vascular endothelial growth factor receptor-2, and integ
32 r docetaxel in combination with ramucirumab (vascular endothelial growth factor receptor 2 antibody)
33 o different human tumor xenografts with anti-vascular endothelial growth factor receptor-2 antibody (
34 s on two human tumor xenografts suggest that vascular endothelial growth factor receptor-2 blockade m
35 murine monocytes expressed F4/80, CD31, and vascular endothelial growth factor receptor 2, but neith
36 ated the JAK/STAT-dependent up-regulation of vascular endothelial growth factor receptor-2 by sIL-6R
38 n antiangiogenic monoclonal antibody against vascular endothelial growth factor receptor-2, can produ
39 injection of neutralizing antibodies against vascular endothelial growth factor receptor 2, CCR3, CC
40 ctor increased, whereas endoglin and soluble vascular endothelial growth factor receptor-2 decreased
41 4 and subsets coexpressing CD133, CXCR4, and vascular endothelial growth factor receptor-2 epitopes.
42 ction, led to a significant up-regulation of vascular endothelial growth factor receptor 2 expression
43 have a significantly lower proliferation and vascular endothelial growth factor receptor 2 expression
44 erns of epidermal growth factor receptor and vascular endothelial growth factor receptor 2 expression
45 lar endothelial growth factor expression and vascular endothelial growth factor receptor-2 expression
46 assay was reduced by an antibody against the vascular endothelial growth factor receptor 2 (FIK-1) an
47 an oral DNA minigene vaccine against murine vascular endothelial growth factor receptor 2 (FLK-1), a
48 beta, epidermal growth factor receptor, and vascular endothelial growth factor receptor 2 (Flk-1), b
49 pression of a soluble, truncated form of the vascular endothelial growth factor receptor-2 (Flk-1), a
52 s embryos express a greatly reduced level of vascular endothelial growth factor receptor-2/Flk-1, con
53 rochrome-conjugated monoclonal antibodies to vascular endothelial growth factor receptor-2 (Flk1) and
55 rmal vessels in mammary tumours, by blocking vascular endothelial growth factor receptor-2, improves
56 discoveries point to the key role played by vascular endothelial growth factor receptor 2 in control
58 cell surface expression of CD133, CD34, and vascular endothelial growth factor receptor-2 in 110 pat
60 ion was inhibited by rapamycin and SU5416 (a vascular endothelial growth factor receptor 2 inhibitor)
64 receptor 1 kinase inhibitor) and oxindole (a vascular endothelial growth factor receptor 2 kinase inh
65 lo[2,1-f][1,2,4]triazine-based inhibitors of vascular endothelial growth factor receptor-2 kinase is
66 Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and
67 s (Lm), we fused polypeptides from the mouse vascular endothelial growth factor receptor 2 molecule (
68 by an endothelial nitric oxide synthase/Akt/vascular endothelial growth factor receptor 2/oxidative
69 The vascular endothelial growth factor receptor 2 phosphoryl
70 owth factor mRNA and protein expression, and vascular endothelial growth factor receptor-2 phosphoryl
71 tyrosine kinase inhibitor, SU11248, inhibits vascular endothelial growth factor receptor 2, platelet-
72 ors are possibly involved in mobilization of vascular endothelial growth factor receptor 2-positive e
73 fluorescent protein under the control of the vascular endothelial growth factor receptor-2 promoter.
74 ur study provides insights into how FLT1 and vascular endothelial growth factor receptor 2 signaling
75 nsity, endothelial nitric oxide synthase/Akt/vascular endothelial growth factor receptor 2 signaling,
76 of endothelial cells largely by antagonizing vascular endothelial growth factor receptor 2 signaling.
78 2.0-5.8; Ptrend = 1.1 x 10(-6)), and soluble vascular endothelial growth factor receptor 2 (sVEGFR2;
79 eta versus other angiogenic receptors (e.g., vascular endothelial growth factor receptor 2, TIE-2, an
80 endothelial cells, we immunized against host vascular endothelial growth factor receptor 2 to fight t
81 sis by altering alpha(v)beta(3) integrin and vascular endothelial growth factor receptor-2 traffickin
82 (n = 22) or a truncated soluble form of the vascular endothelial growth factor receptor-2 (truncated
83 les directed against various targets such as vascular endothelial growth factor receptor-2, vascular
84 ine kinase activity associated with isolated vascular endothelial growth factor receptor 2 (VEGF-R2)
85 ds to an abnormal and persistent increase in vascular endothelial growth factor receptor 2 (VEGF-R2)
86 NF-kappaB) pathways and the up-regulation of vascular endothelial growth factor receptor 2 (VEGF-R2)
87 dothelial transmembrane receptors, Tie-2 and vascular endothelial growth factor receptor 2 (VEGF-R2).
88 th factor receptor beta (PDGF-Rbeta) and the vascular endothelial growth factor receptor 2 (VEGF-R2,
89 tegrins and used to deliver siRNA inhibiting vascular endothelial growth factor receptor-2 (VEGF R2)
90 able, selective, nanomolar inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2)
91 different upstream pathways as inhibition of vascular endothelial growth factor receptor 2 (VEGF2R) o
92 that targets the key angiogenesis receptors vascular endothelial growth factor receptor 2 (VEGFR-2)
94 on of custom designed imaging probes against vascular endothelial growth factor receptor 2 (VEGFR-2)
95 lly as epithelial growth factor receptor and vascular endothelial growth factor receptor 2 (VEGFR-2)
96 ing, BVZ pharmacokinetics, and estimation of vascular endothelial growth factor receptor 2 (VEGFR-2)
97 In murine embryonic stem cells, the onset of vascular endothelial growth factor receptor 2 (VEGFR-2)
98 pyroptosis, improves EC survival mediated by vascular endothelial growth factor receptor 2 (VEGFR-2),
100 ing CD144 or E-selectin, and EPCs expressing vascular endothelial growth factor receptor 2 (VEGFR-2),
101 tified as potent and selective inhibitors of vascular endothelial growth factor receptor-2 (VEGFR-2)
104 the VEGF(165)-induced autophosphorylation of vascular endothelial growth factor receptor-2 (VEGFR-2)
105 direct inhibition of the kinase activity of vascular endothelial growth factor receptor-2 (VEGFR-2)
106 eversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2 (VEGFR-2)
108 erentially expressed during neoangiogenesis: vascular endothelial growth factor receptor-2 (VEGFR-2)
109 hown that coexpression of Stat3alpha and the vascular endothelial growth factor receptor-2 (VEGFR-2)
111 ed to a dose- and time-dependent decrease in vascular endothelial growth factor receptor-2 (VEGFR-2)
112 elet-derived growth factor receptor-beta and vascular endothelial growth factor receptor-2 (VEGFR-2)
113 nd evaluated two compounds that each inhibit vascular endothelial growth factor receptor-2 (VEGFR-2)
114 nce of a splice variant of the gene encoding vascular endothelial growth factor receptor-2 (Vegfr-2)
115 tion of phospholipase Cgamma1 (PLCgamma1) by vascular endothelial growth factor receptor-2 (VEGFR-2)
116 h 6 different antibodies [anti-CD34, -CD31, -vascular endothelial growth factor receptor-2 (VEGFR-2),
117 rs for the receptor tyrosine kinases MET and Vascular Endothelial Growth factor Receptor-2 (VEGFR-2).
123 owth factor receptor 2-IIIb (FGFR2b) and the vascular endothelial growth factor receptor 2 (VEGFR2) a
125 either hematopoietic cell loss of FGFR1/2 or vascular endothelial growth factor receptor 2 (Vegfr2) h
126 (shear stress=12 dyne/cm2) rapidly activates vascular endothelial growth factor receptor 2 (VEGFR2) i
127 this disease is resistant to treatment with vascular endothelial growth factor receptor 2 (VEGFR2) i
128 dimer known to have a high affinity for the vascular endothelial growth factor receptor 2 (VEGFR2) i
130 omparing the effects of DC101, an antimurine vascular endothelial growth factor receptor 2 (VEGFR2) m
131 ation of Cdc42 in ECs decreased the level of vascular endothelial growth factor receptor 2 (VEGFR2) p
133 protein tyrosine phosphatase (SHP)-1 to the vascular endothelial growth factor receptor 2 (VEGFR2) s
135 as a new class of potent and selective human vascular endothelial growth factor receptor 2 (VEGFR2) t
136 tyrosine kinase (Etk), which trans-activates vascular endothelial growth factor receptor 2 (VEGFR2) t
137 several receptor tyrosine kinases, including vascular endothelial growth factor receptor 2 (VEGFR2),
138 mined by their surface expression pattern of vascular endothelial growth factor receptor 2 (VEGFR2),
141 egulate permeabilizing responses directed by vascular endothelial growth factor receptor 2 (VEGFR2),
142 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2),
143 ptide, based on an amyloidogenic fragment of vascular endothelial growth factor receptor 2 (VEGFR2),
144 We apply this strategy to the isolation of vascular endothelial growth factor receptor 2 (VEGFR2)-b
145 enic factors, PRAK is activated by p38 via a vascular endothelial growth factor receptor 2 (VEGFR2)-d
146 ultrasonography (US) by using clinical-grade vascular endothelial growth factor receptor 2 (VEGFR2)-t
147 via Src kinase-dependent transactivation of vascular endothelial growth factor receptor 2 (VEGFR2).
148 ; P=3.8 x 10(-11)), upstream of KDR encoding vascular endothelial growth factor receptor 2 (VEGFR2).
149 rent binding to the alpha2beta1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2).
150 ocking the placental growth factor (PlGF) or vascular endothelial growth factor receptor 2 (VEGFR2).
151 arises from a population that expresses the vascular endothelial growth factor receptor 2 (VEGFR2, F
152 Surprisingly, inhibition of angiogenesis by vascular endothelial growth factor receptor-2 (VEGFR2) b
156 uster of differentiation 34 (CD34+) or CD34+/vascular endothelial growth factor receptor-2 (VEGFR2+)
157 by this chemokine requires the activation of vascular endothelial growth factor receptor-2 (VEGFR2/fe
158 uced angiogenesis requires the activation of vascular endothelial growth factor receptor-2 (VEGFR2/Fl
159 e switch from signal transducing full-length vascular endothelial growth factor receptor-2 (VEGFR2/KD
160 genes, namely matrix metalloproteinase 1 and vascular endothelial growth factor receptor 2, were nega
161 d association/dissociation rate constants of vascular endothelial growth factor receptor-2 with respe
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。